Therapeutics & Pipeline
At week 48, 54% of patients in the open-label ONWARD3 extension achieved PASI 100 with envudeucitinib; three oral agents differ in dosing and responses at scalp, nail, palm and sole sites.
JillWellington / pixabay
Industry & Regulation
Boots launched seven ingestible K-Wellness lines after triple-digit Korean cosmetics growth and more than 200% growth in wellness…
Skin Cancer & Surgery
Intismeran autogene plus pembrolizumab cut recurrence or death risk by 42% in resected stage IIB-IV melanoma at 24.6 months' foll…
Skin Cancer & Surgery
DecisionDx-Melanoma showed a >1% absolute mortality difference in a large SEER analysis, while MERLIN_001 missed its primary endp…
![<![CDATA[Don't Be Rash: Navigating Topical Steroid Withdrawal Concerns in Pediatric Eczema]]>](/media/a8/a8d02fb13ec3d008.1280.webp)
Clinical Dermatology
![<![CDATA[ATTO-1310 Reduces Itch at Week 12 in Chronic Pruritus and Atopic Dermatitis]]>](/media/5c/5cb0148b23c26fa3.1280.webp)
Therapeutics & Pipeline
![<![CDATA[The Practice Brief: New Approvals, Access Barriers, and Evolving Care]]>](/media/45/45c5409dbe10ffdc.1280.webp)
Practice & Policy
Skin Cancer & Surgery
Skin Cancer & Surgery
![<![CDATA[EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma]]>](/media/97/97c736a8cd72f5f6.1280.webp)
Therapeutics & Pipeline
Therapeutics & Pipeline
![<![CDATA[RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy]]>](/media/7e/7e56c92ae53cb6f2.1280.webp)
Skin Cancer & Surgery
![<![CDATA[Women’s Health Needs in Psoriasis and Atopic Dermatitis]]>](/media/2b/2b8340d9f9746c1f.1280.webp)
Inflammatory Disease
![<![CDATA[PASI 100 Rates and Site-Specific Responses With Oral Psoriasis Therapies]]>](/media/32/3274f794269fb35e.1280.webp)
![<![CDATA[A Patient's Psoriasis Journey: From Topicals to Biologic Therapy]]>](/media/a6/a6dabe82c8358568.1280.webp)
![<![CDATA[Bone Alkaline Phosphatase and Growth in Pediatric Atopic Dermatitis]]>](/media/91/919ca59fa780b390.1280.webp)
![<![CDATA[Systemic Therapy Selection in Pediatric and Adult Atopic Dermatitis]]>](/media/fa/fab1168c0c1fd646.1280.webp)
![<![CDATA[Dr Najjar on Data for the Oncolytic Virus VET3-TGI in Advanced Solid Tumors]]>](/media/69/69dc3a2ebbea5955.1280.webp)
![<![CDATA[How Clinicians Can Support Patients With Acral and Mucosal Melanoma]]>](/media/4a/4ad8177256cdaae2.1280.webp)